Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Papaverine for Prostatic Hyperplasia
NCT03064282Phase 1Unknown
- Sponsor
- Manchanda Medical Clinic
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
01
Overview
Phase 1, randomised trial in benign prostatic hyperplasia (BPH) comparing Placebo with Papaverine Arm (2 arms). Primary endpoints: Regression of symptoms at 16 weeks and Prostate-Specific Antigen level at 16 weeks. Status: unknown.
02
Drugs
papaverine
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT03064282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03064282.